Next Article in Journal
COVID-19 in Relation to Polypharmacy and Immunization (2020–2024)
Previous Article in Journal
Review of the Effects of Antiviral Therapy on Hepatitis B/C-Related Mortality and the Regression of Fibrosis
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Article

Comparison of Chikungunya Virus-Induced Disease Progression and Pathogenesis in Type-I Interferon Receptor -Deficient Mice (A129) and Two Wild-Type (129Sv/Ev and C57BL/6) Mouse Strains

1
UK Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire SP4 0JG, UK
2
Medicines and Healthcare Products Regulatory Agency (MHRA), Blanche Ln, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK
*
Author to whom correspondence should be addressed.
Viruses 2024, 16(10), 1534; https://doi.org/10.3390/v16101534
Submission received: 23 July 2024 / Revised: 10 September 2024 / Accepted: 20 September 2024 / Published: 27 September 2024

Abstract

Chikungunya virus (CHIKV) is a mosquito-borne alphavirus causing a debilitating febrile illness with rheumatic disease symptoms of arthralgia and arthritis. Since its spread outside of Africa in 2005, it continues to cause outbreaks and disseminates into new territories. Intervention strategies are urgently required, including vaccination and antiviral approaches. To test efficacy, the use of small animal models is required. Two mouse strains, A129, with a deficiency in their type-I interferon (IFN) receptor, and C57BL/6 are widely used. A direct comparison of these strains alongside the wild-type parental strain of the A129 mice, 129Sv/Ev, was undertaken to assess clinical disease progression, viral loads in key tissues, histological changes and levels of sera biomarkers. Our results confirm the severe disease course in A129 mice which was not observed in the parental 129Sv/Ev strain. Of the two wild-type strains, viral loads were higher in 129Sv/Ev mice compared to C57BL/6 counterparts. Our results have established these models and parameters for the future testing of vaccines and antiviral approaches.
Keywords: Chikungunya; mouse; model; preclinical; pathogenesis Chikungunya; mouse; model; preclinical; pathogenesis

Share and Cite

MDPI and ACS Style

Graham, V.A.; Easterbrook, L.; Rayner, E.; Findlay-Wilson, S.; Flett, L.; Kennedy, E.; Fotheringham, S.; Kempster, S.; Almond, N.; Dowall, S. Comparison of Chikungunya Virus-Induced Disease Progression and Pathogenesis in Type-I Interferon Receptor -Deficient Mice (A129) and Two Wild-Type (129Sv/Ev and C57BL/6) Mouse Strains. Viruses 2024, 16, 1534. https://doi.org/10.3390/v16101534

AMA Style

Graham VA, Easterbrook L, Rayner E, Findlay-Wilson S, Flett L, Kennedy E, Fotheringham S, Kempster S, Almond N, Dowall S. Comparison of Chikungunya Virus-Induced Disease Progression and Pathogenesis in Type-I Interferon Receptor -Deficient Mice (A129) and Two Wild-Type (129Sv/Ev and C57BL/6) Mouse Strains. Viruses. 2024; 16(10):1534. https://doi.org/10.3390/v16101534

Chicago/Turabian Style

Graham, Victoria A., Linda Easterbrook, Emma Rayner, Stephen Findlay-Wilson, Lucy Flett, Emma Kennedy, Susan Fotheringham, Sarah Kempster, Neil Almond, and Stuart Dowall. 2024. "Comparison of Chikungunya Virus-Induced Disease Progression and Pathogenesis in Type-I Interferon Receptor -Deficient Mice (A129) and Two Wild-Type (129Sv/Ev and C57BL/6) Mouse Strains" Viruses 16, no. 10: 1534. https://doi.org/10.3390/v16101534

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.
Back to TopTop